News details

 
Information title

Epix regains commercialization rights to Vasovist

Published on Thursday 04 September 2008 - 16:42

Summary :
Bayer Schering Pharma is handing back the worldwide commercialization rights to Epix's Vasovist, an MRA agent that has yet to win FDA approval. Their deal ends on March 1, 2009 and Bayer Schering...
Read more

Information source

http://www.fiercebiotech.com/news/frontpage

Website description
Get the latest news on the biotech industry, biotech companies, FDA approval and clinical research. Sign up today for the biotech industry

Articles published on this website : 1 / 7 days - 4 / 30 days

Roche snaps up Memory Pharma for $50M Merck drug fails to improve Alzheimer's symptoms TorreyPines sells Alzheimer's rights to Eisai Medivation hands out big bonuses after Pfizer deal Fidelity invests $65 in EnVivo Pharma, takes over

Other articles published on other websites on the same day

Time Domain Delivers Ultra Wideband (UWB) Real-Time Precision Location of Alzheimer's Patients, Staff and Equipment at Nesconset Center for Nursing... http://www.prnewswire.com/ Alzheimer's Society Comment On New Research Demonstrating That Exercise Improves Cognition In People With Mild Cognitive Impairment, Published In JAMA http://www.medicalnewstoday.com/ Pfizer's Found Innovation at Medivation http://seekingalpha.com/ Rhode Island Hospital study finds link between obesity, type 2 diabetes and neurodegeneration http://www.eurekalert.org/ Pfizer Shells Out Millions To Help Bay Area Biotech Company http://www.nbc11.com/ APPRECIATION: Gould never just a coach http://www.dailynewstribune.com/ Alzheimer's support group meeting Sept. 18 http://nbs.gmnews.com/